PT  - JOURNAL ARTICLE
AU  - Huang, Yen-Tsung
AU  - Lai, En-Yu
AU  - Su, Jia-Ying
AU  - Lu, Hsueh-Ju
AU  - Chen, Yen-Lin
AU  - Wu, Jer-Yuarn
AU  - Wei, Chun-yu
AU  - Li, Ling-Hui
AU  - Fann, Cathy S.-J.
AU  - Yang, Hsin-Chou
AU  - Chen, Chien-Hsiun
AU  - Chen, Hung-Hsin
AU  - Liu, Yi-Min
AU  - Tsai, Ming-Fang
AU  - Yeh, Erh-Chan
AU  - Cheng, Chih-Kuang
AU  - Wang, Yen-Po
AU  - Chi, Nai-Fang
AU  - Lee, I-Cheng
AU  - Chen, Harn-Shen
AU  - Hsieh, Yun-Cheng
AU  - Liao, Yi-Chu
AU  - Hsu, Shao-Jung
AU  - Ou, Shuo-Ming
AU  - Lai, Kuan-Lin
AU  - Lin, Chung-Chi
AU  - Chen, Yi-Jen
AU  - Chang, Chia-Ming
AU  - Wang, Peng-Hui
AU  - Luo, Yung-Hung
AU  - Chang, Yun-Ting
AU  - Chen, Chih-Chiang
AU  - Hsieh, Yu-Cheng
AU  - Chen, Yi-Ming
AU  - Hsiao, Tzu-Hung
AU  - Lin, Ching-Heng
AU  - Chen, Yen-Ju
AU  - Chen, I-Chieh
AU  - Mao, Chien-Lin
AU  - Chang, Shu-Jung
AU  - Chang, Yen-Lin
AU  - Liao, Yi-Ju
AU  - Lai, Chih-Hung
AU  - Lee, Wei-Ju
AU  - Tung, Hsin
AU  - Yen, Ting-Ting
AU  - Yen, Hsin-Chien
AU  - Chang, Shy-Shin
AU  - Chang, Yu-Sheng
AU  - Lee, Ting-I
AU  - Yeh, Shauh-Der
AU  - Wu, Mei-Yi
AU  - Wu, Ming-Shun
AU  - Tsai, Lung Wen
AU  - Zheng, Cai-mei
AU  - Chien, Yu-Mei
AU  - Lin, Tsung-Hsien
AU  - Chen, Yen-Hsu
AU  - Lan, Cheng-Che E.
AU  - Yen, Jeng-Hsien
AU  - Liang, Wen-Chen
AU  - Chan, Te-Fu
AU  - Chiou, Shyh-Shin
AU  - Chuang, Shih-Chang
AU  - Hwang, Shang-Jyh
AU  - Lin, Yi-Jung
AU  - Huang, Yu-Chuang
AU  - Li, Wan-Ru
AU  - Chen, Tsai-Chuan
AU  - Huang, Wei-Ting
AU  - Chen, Kuan-Chih
AU  - Lim, Shin-Yee
AU  - Shen, Yi-Shiuan
AU  - Huang, Chia-Chia
AU  - Chen, Chien-Hung
AU  - Tian, Ya-Chung
AU  - Chen, Chia-Ling
AU  - Fang, Yao-Fan
AU  - Fang, Ji-Tseng
AU  - Yen, Yi-Hao
AU  - Wu, Wei-Chi
AU  - Huang, Wen-Shih
AU  - Sun, Chi-Chin
AU  - Chen, Mei-Jyh
AU  - Lin, Ching-Hung
AU  - Yang, Tsung-Hua
AU  - Lee, Pei-Lin
AU  - Wang, Ming-Yang
AU  - Tsai, Tsen-Fang
AU  - Su, Tung-Hung
AU  - Liou, Jyh-Ming
AU  - Yang, Shun-Fa
AU  - Hsieh, Chia-Chuan
AU  - Sung, Chih-Chien
AU  - Kuo, Feng-Chih
AU  - Lin, Shih-Hua
AU  - Hueng, Dueng-Yuan
AU  - Lin, Chien-Jung
AU  - Shen, Hueng-Yuan
AU  - Hsieh, Chang-Hsun
AU  - Lin, Shinn-Zong
AU  - Wang, Tso-Fu
AU  - Ho, Tsung-Jung
AU  - Shueng, Pei-Wei
AU  - Hsieh, Chen-Hsi
AU  - Jeng, Kuo-Shyang
AU  - Ma, Gwo-Chin
AU  - Chang, Ting-Yu
AU  - Chiang, Han-Sun
AU  - Lin, Yi-Tien
AU  - Kao, Kuo-Jang
AU  - Hung, Chen-Fang
AU  - Fang, I-Mo
AU  - Chen, Po-Yueh
AU  - Tsui, Kochung
AU  - Kwok, Pui-Yan
AU  - Yao, Wei-Jen
AU  - Chen, Shiou-Sheng
AU  - Chen, Ming
AU  - Huang, Chih-Yang
AU  - Wang, Da-Wei
AU  - Chen, Chun-houh
TI  - Deleterious Variants Contribute Minimal Excess Risk in Large-Scale Testing
AID  - 10.1101/2024.10.21.24315653
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.21.24315653
4099  - http://medrxiv.org/content/early/2024/10/22/2024.10.21.24315653.short
4100  - http://medrxiv.org/content/early/2024/10/22/2024.10.21.24315653.full
AB  - DNA sequencing of patients with rare disorders has been highly successful in identifying “causal variants” for numerous conditions. However, there are many reports of healthy individuals who harbor these deleterious variants, leading to the concept of incomplete penetrance and doubt about the utility of genetic testing in clinical practice and population screening. As the deleterious variants are rare, the penetrance of these variants in the population is largely unknown. We analyzed the genetic and clinical data from 486,956 participants of the Taiwan Precision Medicine Initiative (TPMI) to determine the risk difference between those with and without deleterious variants. In all, we analyzed 292 disease-relevant variants and their clinical outcomes to assess their association. We found that only 15 variants show a risk difference exceeding 5% between those with or without the variants. In essence, 87.3% of deleterious variants exhibit minimal risk differences, suggesting a limited impact on the individual and population levels. Our analysis revealed increasing trends with age in six cardiovascular and degenerative diseases and bell-shaped trends in two cancers. Additionally, we identified three clinical outcomes exhibiting a dose-response relationship with the number of deleterious variants. Our findings show that large-scale testing of deleterious variants found in the literature is not warranted, except for those exhibiting large disease risk differences.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the following agencies (grant numbers): Academia Sinica (40-05-GMM, AS-GC-110-MD02, 236e-110020) and National Development Fund, Executive Yuan (NSTC 111-3114-Y-001-001).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards of 17 institutes: 1.Academia Sinica (AS-IRB01-18079), 2.Taipei Veterans General Hospital (2020-08-014A), 3.National Taiwan University Hospital (201912110RINC), 4.Tri-Service General Hospital (2-108-05-038), 5.Chang Gung Memorial Hospital (201901731A3), 6.Taipei Medical University Healthcare System (N202001037), 7.Chung Shan Medical University Hospital (CS19035), 8.Taichung Veterans General Hospital (SF19153A), 9.Changhua Christian Hospital (190713), 10.Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUHIRB-SV(II)-20190059), 11.Hualien Tzu Chi Hospital (IRB108-123-A), 12.Far Eastern Memorial Hospital (110073-F), 13.Ditmanson Medical Foundation Chia-Yi Christian Hospital (IRB2021128), 14.Taipei City Hospital (TCHIRB-10912016), 15.Koo Foundation Sun Yat-Sen Cancer Center (20190823A), 16.Cathay General Hospital (CGH-P110041), 17.Fu Jen Catholic University Hospital (FJUH109001).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe genotyping and electronic medical record (EMR) data analyzed in this study are from the Taiwan Precision Medicine Initiative (TPMI) with proper approval from the TPMI Data Access Committee. In compliance with the confidentiality laws governing genetic and health data in Taiwan, the de-identified TPMI data are kept in a secure server at the Academia Sinica and not released to the public. Researchers requesting access to the individual genotyping and EMR data can do so on a collaborative basis. Instructions on requesting access to the data can be found on the TPMI official website (https://tpmi.ibms.sinica.edu.tw/www/en/). https://tpmi.ibms.sinica.edu.tw/www/en/